Session Item

We hypothesise that partial-breast radiotherapy restricted to the vicinity of the original tumour, in women with favourable early-stage breast cancer, treated with 3D-RT in five sessions, is safe and effective treatment. We present the experience in our department with patients treated with this regimen under routine clinical practice conditions, reporting short-term toxicity and efficacy outcomes.

Women diagnosed with breast cancer, who were aged 45 years or older who had breast-conserving surgery for unifocal invasive ductal adenocarcinoma of any grade. Other inclusion criteria were pathological tumour 3 cm or less (pT1–2), axillary node negative and minimum microscopic margins of 2 mm or more. All the patients have been treated with external radiotherapy, with 3D. During treatment patients positions was verificated using cone-beam CT. A dose of 30 Gy en five non-consecutive daily fractions at 6 Gy/ fraction was prescribed.

Between January 2017 and December 2021 we treated 228 patients, a median follow-up of 36.4 months (5.9–51.9), a median aged 61 (41-86) years old. The average tumor was 12 mm (2 to 39 mm). The tumor: pT1: 89%, pT2:11%. Phenotype: 88% Luminal. No local or regional recurrence was observed. Early skin reactions: no documented toxicity according Radiation Therapy Oncology Group (RTOG) in 116 (51%), grade I: 104 (46%), grade II: 7 (3%). No late skin toxicity Grade II, III.

Accelerated partial breast irradiation has developed as alternative radiation techniques for select patients with favourable early-stage breast cancer. These radiation regimens are safe and allow for greater patient convenience (fewer sessions).